Drug intelligence / Profile preview

CTS2711

Development stage: Preclinical
Lead developer: CytosinLab
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

CTS2711 is an investigational DNA-modulating agent developed by CytosinLab, specifically targeting solid tumors with TP53 deletions or mutations. While the precise molecular mechanism of action remains undisclosed, the drug is designed to exploit the genetic vulnerabilities of p53-deficient cancer cells through DNA modulation. It represents part of CytosinLab's broader portfolio focused on epigenetic therapies and DNA-targeted interventions for high-need oncological indications.

Targets

DNA

Beyond the preview

Go deeper on CTS2711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTS2711.

Explore the full profile